POST-TEST

The First Annual Miami General Medical Oncology Symposium

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. The results of the Phase III 4. The Phase III iLLUMINATE trial IMpassion130 trial of nab paclitaxel in evaluating either ibrutinib or chloram- combination with either bucil in combination with or placebo for patients with previously for treatment-naïve chronic lymphocytic untreated metastatic triple-negative leukemia or small lymphocytic breast cancer demonstrated a statis- lymphoma demonstrated a statisti- tically significant improvement in cally significant improvement in PFS ______with atezolizumab in the with ibrutinib/obinutuzumab in which intent-to-treat population. population of patients? a. Overall survival a. Intention-to-treat population b. Progression-free survival (PFS) b. Population with high-risk c. Both a and b cytogenetic abnormalities c. Both a and b 2. The ongoing Phase III FORWARD I d. Neither a nor b trial is investigating the anti-folate receptor alpha antibody-drug conjugate 5. In the Phase III COLUMBUS trial ______versus investigator’s choice evaluating the combination of of chemotherapy for women with folate encorafenib and binimetinib versus receptor alpha-positive advanced monotherapy with vemurafenib or epithelial ovarian cancer. encorafenib for patients with unresect- a. Niraparib able or metastatic melanoma and b. Lifastuzumab vedotin BRAF V600 mutations, encorafenib/ c. Duvelisib binimetinib demonstrated a statistically significant improvement in ______d. Mirvetuximab soravtansine in comparison to vemurafenib. e. Obinutuzumab a. Overall survival 3. In the Phase III RELEVANCE trial b. PFS comparing lenalidomide/ c. The incidence of photosensitivity (R2) to rituximab/chemotherapy, each d. The incidence of rash followed by maintenance rituximab, e. All of the above for patients with previously untreated f. All except d Grade I to Grade IIIa follicular lymphoma requiring treatment according to the g. All except e GELF criteria, the R2 regimen demon- h. Both a and b strated ______. 6. The results of the Phase III CELESTIAL a. A similar efficacy profile in terms trial of cabozantinib for patients with of overall survival and PFS advanced hepatocellular cancer who b. Less frequent cutaneous reactions, had previously received sorafenib tumor flare and diarrhea demonstrated a statistically signifi- c. More febrile neutropenia and cant improvement in ______with neuropathy cabozantinib compared to placebo. d. All of the above a. Overall survival e. None of the above b. PFS c. Objective response rate d. All of the above e. Both a and c f. Both b and c POST-TEST

The First Annual Miami General Medical Oncology Symposium

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 7. The results of the Phase III KEYNOTE- 9. Which of the following statements is true 181 trial evaluating about the EGFR inhibitor osimertinib in versus investigator’s choice of paclitaxel, the management of non-small cell lung docetaxel or irinotecan for patients with cancer (NSCLC)? locally advanced or metastatic adeno- a. Osimertinib is FDA approved as carcinoma or squamous cell carcinoma first-line therapy for patients with of the esophagus who experienced metastatic NSCLC harboring EGFR disease progression after standard exon 19 deletions or exon 21 first-line therapy demonstrated a statisti- L858R mutations cally significant improvement in overall b. Osimertinib is FDA approved survival with pembrolizumab in which as first-line therapy for patients population? with metastatic NSCLC harboring a. Intention-to-treat population uncommon EGFR mutations such b. Patients with a PD-L1 combined as G719X and L861Q mutations positive score of 10 or higher c. Osimertinib has demonstrated c. Patients with squamous cell carci- better CNS activity in comparison noma to erlotinib or gefitinib d. All of the above d. Osimertinib causes less Grade 2 or e. Both a and b 3 rash in comparison to erlotinib or f. Both a and c gefitinib g. Both b and c e. All of the above f. All except b 8. The ongoing Phase III TITAN trial g. All except c is comparing the androgen receptor h. All except d antagonist ______in combination with androgen-deprivation therapy to 10. Common symptoms of the cytokine androgen-deprivation therapy alone release syndrome associated with for patients with metastatic hormone- chimeric antigen receptor T-cell therapy sensitive prostate cancer. include ______. a. Enzalutamide a. High fevers b. Abiraterone acetate b. Dyspnea/hypoxia c. Apalutamide (ARN-509) c. Encephalopathy d. Darolutamide (ODM-201) d. Pruritic rash e. Alopecia f. All of the above g. b, c and d h. a, b and d i. a, b and c j. All except c